Resources
Practical, sourced guidance for prescribing providers and compounding pharmacies: peptides, GLP-1s, 503A vs 503B, sourcing, and growth.
A Class II nationwide recall of compounded tirzepatide for lack of sterility assurance, what the FDA record does and does not establish, and how to vet a pharmacy.
For ProvidersHHS will not act against licensed pharmacies and physicians compounding BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax under set conditions. What the interim policy is, what it is not, and what to check before you prescribe or compound.
For ProvidersHow to read a peptide Certificate of Analysis: what section 503A actually requires, why purity is not content, and the red flags that should stop an order.
For PharmaciesA CurifyLabs printer went live at a Washington compounding pharmacy in September 2026. What automation actually changes for 503A margins, and what it does not.
For ProvidersA plain account of the 2026 crackdown on compounded GLP-1s: 30 telehealth warning letters, nearly 1,700 adverse event reports, the 503B bulks-list exclusion, the clinical concerns, and what still lawful compounding looks like.
For ProvidersWhere ivermectin and cancer actually stand in 2026: the trials, the observational data and its caveats, ASCO’s guidance, state OTC laws, and how PEPTPlus pharmacies fit in.
For ProvidersA federal conviction, overprescribing allegations, and DTC telehealth research point to one flaw: platforms and pharmacies paid for volume. How PEPTPlus differs.
For ProvidersOn July 23, 2026, the FDA compounding advisory committee voted to add four peptides to the 503A list. What the vote does, what it does not, and what changes for prescribers.
For ProvidersFDA’s July 2026 peptide advisory panel, the EVEXIAS Category 2 lawsuit, and RFK Jr’s influence, explained for clinicians and compounding pharmacies deciding how to act.
For ProvidersWorried a compounded GLP-1 line is a compliance landmine? Learn how to prescribe compounded semaglutide in 2026: the 503A path, documentation, and safe sourcing.
For ProvidersA BPC-157 prescribing guide for clinicians: what the 2026 reclassification changed, why Category 2 removal is not FDA approval, and how to source compliantly.
For PharmaciesHow to get more prescriptions for your compounding pharmacy without a rep network: win provider referrals, keep your margin, and turn verified quality into demand.
For ProvidersA practical guide to how to add peptide therapy to your practice: the compliance, sourcing, and fulfillment hurdles, and how a verified marketplace removes them.
For PharmaciesThe difference between 503A and 503B compounding pharmacies: oversight, office stock, cGMP vs USP, and where peptides and GLP-1s land in 2026, from primary FDA sources.
For PharmaciesA 2026 guide to compounding pharmacy marketing: what actually drives patient search and prescriber referrals, how to stay compliant, and how to grow without a sales team.